Journal ArticleDOI
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
W. Ian McDonald,A Compston,Gilles Edan,Donald E. Goodkin,Hans-Peter Hartung,Fred D. Lublin,Henry F. McFarland,Donald W. Paty,Chris H. Polman,Stephen C. Reingold,Magnhild Sandberg-Wollheim,William A. Sibley,Alan J. Thompson,Stanley van den Noort,Brian Y. Weinshenker,Jerry S. Wolinsky +15 more
Reads0
Chats0
TLDR
The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.Abstract:
The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in both time and space. Magnetic resonance imaging is integrated with dinical and other paraclinical diagnostic methods. The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including "monosymptomatic" disease suggestive of MS, disease with a typical relapsing-remitting course, and disease with insidious progression, without clear attacks and remissions. Previously used terms such as "clinically definite" and "probable MS" are no longer recommended. The outcome of a diagnostic evaluation is either MS, "possible MS" (for those at risk for MS, but for whom diagnostic evaluation is equivocal), or "not MS."read more
Citations
More filters
Journal ArticleDOI
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
Lenka Novakova,Markus Axelsson,Mohsen Khademi,Henrik Zetterberg,Kaj Blennow,Clas Malmeström,Fredrik Piehl,Tomas Olsson,Jan Lycke +8 more
TL;DR: Reduced inflammatory activity (CXCL13, CHI3L1, and CHIT1) and reduced axonal damage (NFL) in patients switching from first-line DMTs to fingolimod indicate similar effects on inflammatory and degenerative processes.
Journal ArticleDOI
Immunmodulatorische Stufentherapie der multiplen Sklerose
TL;DR: Natalizumab is only approved for monotherapy after basic treatment has failed or for rapidly progressive relapsing-remitting MS, as new developments in the diagnostic work-up and immunotherapy of multiple sclerosis as well as optimization of medical care for MS patients are reflected.
Journal ArticleDOI
Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis,
Lynne Shinto,Gail Marracci,Sara Baldauf-Wagner,A. Strehlow,A. Strehlow,Vijayshree Yadav,Vijayshree Yadav,L. Stuber,Dennis Bourdette,Dennis Bourdette +9 more
TL;DR: Omega-3 FA significantly decreased MMP-9 levels in RRMS and may act as an immune-modulator that has potential therapeutic benefit in MS patients and is coupled with a significant increase in omega-3FA levels in red blood cell membranes.
Journal ArticleDOI
Revised definition of neuropathic pain and its grading system: an open case series illustrating its use in clinical practice.
Christian Geber,Ulf Baumgärtner,R. Schwab,Harald D. Müller,Peter Stoeter,Marianne Dieterich,Clemens Sommer,Frank Birklein,Rolf-Detlef Treede +8 more
TL;DR: This open case series of 5 outpatients demonstrates how the grading system can be applied, in combination with appropriate confirmatory testing, to diagnosis neuropathic conditions in clinical practice.
Journal ArticleDOI
Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients.
Andrea Brioschi,Sandrine Gramigna,Esther Werth,Fabienne Staub,Christiane Ruffieux,Claudio L. Bassetti,Myriam Schluep,Jean-Marie Annoni +7 more
TL;DR: Modafinil was tolerated in 75% of patients at small doses and seemed to improve the severity of fatigue in the MS and BDS groups but not in the CS group, and there was no modification in measured physical activity.
References
More filters
Journal ArticleDOI
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Charles M. Poser,Donald W. Paty,Labe C. Scheinberg,W I McDonald,F A Davis,George C. Ebers,Kenneth P. Johnson,William A. Sibley,Donald H. Silberberg,Wallace W. Tourtellotte +9 more
TL;DR: Today there is a need for more exact criteria than existed earlier in order to conduct therapeutic trials in multicenter programs, to compare epidemiological surveys, to evaluate new diagnostic procedures, and to estimate the activity of the disease process in MS.
Journal ArticleDOI
The clinical course of neuromyelitis optica (Devic's syndrome)
TL;DR: Clinical, laboratory, and imaging features generally distinguish neuromyelitis optica from MS, and patients with relapsing optic neuritis and myelitis may have neuromyeliitis opticas rather than MS.
Journal ArticleDOI
Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis.
George A. Schumacher,Gilbert Beebe,Robert F. Kibler,Leonard T. Kurland,John F. Kurtzke,Fletcher McDowell,Benedict Nagler,William A. Sibley,Wallace W. Tourtellotte,Thomas L. Willmon +9 more
TL;DR: Since its etiology and pathogenesis have eluded detection, it is not surprising that therapeutic attempts have been empiric and often unscientific.
Journal ArticleDOI
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Frederik Barkhof,Massimo Filippi,David Miller,Philip Scheltens,Adriana Campi,Chris H. Polman,Giancarlo Comi,Herman J. Adèr,N. A. Losseff,Jacob Valk +9 more
TL;DR: It is concluded that a four-parameter dichotomized MRI model including gadolinium-enhancement, juxtacortical, infratentorial and periventricular lesions best predicts conversion to clinically definite multiple sclerosis.
Journal ArticleDOI
MRI in the diagnosis of MS A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT
Donald W. Paty,Joel Oger,Lorne F. Kastrukoff,S. A. Hashimoto,John P. Hooge,Andrew Eisen,K. A. Eisen,S. J. Purves,M. D. Low,V. Brandejs,W. D. Robertson,David Kb Li +11 more
TL;DR: MRI was the best method for demonstrating dissemination in space and laboratory-supported definite MS (LSDMS) could be diagnosed in 85 patients of the total 200, and MRI predicted that diagnosis in 18/19 (95%).
Related Papers (5)
Rating neurologic impairment in multiple sclerosis An expanded disability status scale (EDSS)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more